As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and ...

A new study led by scientists at The Wistar Institute, in collaboration with the University of Pennsylvania Perelman School ...

Publication information: “Modulation of lipid nanoparticle-formulated plasmid DNA drives innate immune activation promoting adaptive immunity,” from Cell Reports Medicine ...

A novel strategy using lipid nanoparticles to reprogram liver immunity shows promise in generating antitumor responses ...

Imagine if antibodies, hormones for fertility, proteins like insulin, and vaccines could be swallowed instead of taken by ...

Barclays 27th Annual Global Healthcare Conference March 11, 2025 1:30 PM ETCompany ParticipantsRose Loughlin - EVP of ...

The door may now be open for additional challenges to patents covering mRNA vaccine technologies, paving the way for increased competition in the ...

Moderna (NasdaqGS:MRNA) recently experienced a notable 10% price increase over the last week amidst significant legal and financial developments. Genevant Sciences and Arbutus Biopharma have expanded ...

Genevant Sciences and Arbutus Biopharma have expanded their patent litigation against Moderna internationally, targeting its lipid nanoparticle technology, which could impact products like ...

Second, and again despite having many different options, Pfizer and BioNTech copied Moderna's approach to encode for the full-length spike protein in a lipid nanoparticle formulation for a ...

Objective This study aimed to establish HAV and HEV infections in multiple small animals by intravenously injecting lipid nanoparticle (LNP)-encapsulated full-length viral RNAs (LNP-vRNA). Design In ...